Regorafenib

Last Updated: 06/30/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 2448 publications

Anionic Nanoparticles Co-Loaded with Regorafenib/Paclitaxel for Macrophage-Mediated Chemoimmunotherapy against Colorectal Peritoneal Metastases.

Anionic Nanoparticles Co-Loaded with Regorafenib/Paclitaxel for Macrophage-Mediated Chemoimmunotherapy against Colorectal Peritoneal Metastases.

Journal: Nano letters

Published: May 22, 2026

Efficacy and safety of TAS-102 followed by regorafenib or reverse sequence in later-line treatment of metastatic colorectal cancer: a systematic review and meta-analysis.

Efficacy and safety of TAS-102 followed by regorafenib or reverse sequence in later-line treatment of metastatic colorectal cancer: a systematic review and meta-analysis.

Journal: Chinese clinical oncology

Published: May 21, 2026

A comprehensive analysis of the adverse drug events of metastatic and unresectable gastrointestinal stromal tumor treatment options: avapritinib, imatinib, regorafenib, ripretinib, and sunitinib safety insights and implications.

A comprehensive analysis of the adverse drug events of metastatic and unresectable gastrointestinal stromal tumor treatment options: avapritinib, imatinib, regorafenib, ripretinib, and sunitinib safety insights and implications.

Journal: Future science OA

Published: May 15, 2026

Lessons From GBM AGILE's Regorafenib Experience in Newly Diagnosed and Recurrent Glioblastoma.

Lessons From GBM AGILE's Regorafenib Experience in Newly Diagnosed and Recurrent Glioblastoma.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: May 12, 2026

Gods do play dice: The activity of regorafenib in glioblastoma not confirmed.

Gods do play dice: The activity of regorafenib in glioblastoma not confirmed.

Journal: Neuro-oncology

Published: May 07, 2026

Erratum: Evaluation of Regorafenib in Newly Diagnosed and Recurrent Glioblastoma: GBM AGILE Phase II/III Bayesian Randomized Platform Trial.

Erratum: Evaluation of Regorafenib in Newly Diagnosed and Recurrent Glioblastoma: GBM AGILE Phase II/III Bayesian Randomized Platform Trial.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: May 07, 2026

Macrophage-Derived PDGF-BB and GDF-15 Promote Drug Resistance in KRAS-Mutant Colorectal Cancer.

Macrophage-Derived PDGF-BB and GDF-15 Promote Drug Resistance in KRAS-Mutant Colorectal Cancer.

Journal: bioRxiv : the preprint server for biology

Published: May 07, 2026

Prolonged multimodal disease control with trifluridine/tipiracil plus bevacizumab in KRAS-mutant metastatic rectal cancer: a case report.

Prolonged multimodal disease control with trifluridine/tipiracil plus bevacizumab in KRAS-mutant metastatic rectal cancer: a case report.

Journal: Anti-cancer drugs

Published: May 02, 2026

Designing of sorafenib analogs to target c-Raf for the management of hepatocellular carcinoma: Molecular dynamics and mmPBSA analysis.

Designing of sorafenib analogs to target c-Raf for the management of hepatocellular carcinoma: Molecular dynamics and mmPBSA analysis.

Journal: Journal of bioinformatics and computational biology

Published: April 21, 2026

Synthesis and characterization of bevacizumab-functionalized nanoliposomes loaded with regorafenib and fluorescent carbon dots for triple-negative breast cancer theranostics.

Synthesis and characterization of bevacizumab-functionalized nanoliposomes loaded with regorafenib and fluorescent carbon dots for triple-negative breast cancer theranostics.

Journal: RSC advances

Published: April 20, 2026

Evaluation of Regorafenib in Newly Diagnosed and Recurrent Glioblastoma: GBM AGILE Phase II/III Bayesian Randomized Platform Trial.

Evaluation of Regorafenib in Newly Diagnosed and Recurrent Glioblastoma: GBM AGILE Phase II/III Bayesian Randomized Platform Trial.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: April 14, 2026

Functional Exploration of African Colorectal Cancer Patients Using Personalised Drosophila Avatars.

Functional Exploration of African Colorectal Cancer Patients Using Personalised Drosophila Avatars.

Journal: bioRxiv : the preprint server for biology

Published: April 10, 2026

Showing 1-12 of 2,448

Last Updated: 06/30/2026